Results 11 to 20 of about 3,341,399 (277)

Methodological Issues in Antifungal Susceptibility Testing of Malassezia pachydermatis [PDF]

Journal of Fungi, 2017
Reference methods for antifungal susceptibility testing of yeasts have been developed by the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antibiotic Susceptibility Testing (EUCAST).
Andrea Peano, Mario Pasquetti, Paolo Tizzani, Elisa Chiavassa, Jacques Guillot, Elizabeth Johnson   +5 more
doaj   +3 more sources

New approaches for antifungal susceptibility testing [PDF]

Clinical Microbiology and Infection, 2017
BACKGROUND: Invasive fungal diseases, including those caused by (multi)drug-resistant Candida and Aspergillus species, still represent global public health concerns.
Brunella Posteraro, Maurizio Sanguinetti
exaly   +3 more sources

How to: interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST).

Clinical Microbiology and Infection, 2020
BACKGROUND EUCAST has revised the definition of the susceptibility category "I" from "Intermediate" to "Susceptible, Increased exposure". This implies that "I" can be used where the drug-concentration at the site of infection is high, either because of ...
M. Arendrup, N. Friberg, Mihai Mareș, Gunnar Kahlmeter, J. Meletiadis, J. Guinea, C. Andersen, S. Arikan-Akdağli, F. Barchiesi, E. Chryssanthou, Petr Hamal, H. Järv, N. Klimko, O. Kurzai, K. Lagrou, C. Lass-Flörl, T. Matos, K. Muehlethaler, Thomas R. Rogers, A. Velegraki, S. Arıkan   +20 more
semanticscholar   +2 more sources

Antifungal susceptibility testing for yeasts: how, when and why, according to the new EUCAST guidelines

Microbiologia Medica, 2011
Antifungal susceptibility testing of yeasts and the development of interpretive breakpoints are nowadays very important topics both for the increasing incidence of invasive mycoses and number of available antifungal drugs and for the appearance of ...
Esther Manso, Claudio Farina, Stefano Andreoni, Marco Conte, Paolo Fazii, Gianluigi Lombardi, Silvana Sanna   +6 more
doaj   +2 more sources

Evaluation of antifungal susceptibility testing in Candida isolates by Candifast and disk-diffusion method

Indian Journal of Pathology and Microbiology, 2014
With the increase in invasive fungal infections due to Candida species and resistance to antifungal therapy, in vitro antifungal susceptibility testing is becoming an important part of clinical microbiology laboratories.
Sidhartha Giri, Anupma Jyoti Kindo
doaj   +2 more sources

Antifungal susceptibility testing of vulvovaginal Candida species among women attending antenatal clinic in tertiary care hospitals of Peshawar

Infection and Drug Resistance, 2018
Background Vulvovaginal candidiasis (VVC) is considered as a pervasive gynecological problem among women worldwide. Owing to this fact, in the current study, we aimed at assessing the prevalence rate of Candida spp.
Mariam Khan, J. Ahmed, Amina Gul, A. Ikram, F. Lalani   +4 more
semanticscholar   +2 more sources

Impact of the Disk Diffusion Test on Fluconazole De-Escalation in Patients with Candidemia

Journal of Fungi, 2022
Disk diffusion (DD) is a simple antifungal susceptibility method for Candida. This study examined the impact of fluconazole DD testing on antifungal de-escalation.
Suchavadee Tantasuwan, Piriyaporn Chongtrakool, Amiroh Waesamaae, Methee Chayakulkeeree   +3 more
doaj   +1 more source

Antifungal Susceptibility Testing Identifies the Abdominal Cavity as a Source of Candida glabrata-Resistant Isolates

Antimicrobial Agents and Chemotherapy, 2021
To identify unrecognized niches of resistant Candida isolates and compartmentalization, we retrospectively studied the antifungal susceptibility of 1,103 Candida spp.
Judith Díaz-García, Aina Mesquida, A. Gómez, M. Machado, P. Martín-Rabadán, L. Alcalá, C. Sánchez-Carrillo, E. Reigadas, T. Vicente, P. Muñoz, P. Escribano, J. Guinea   +11 more
semanticscholar   +1 more source

EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents

Clinical Microbiology and Infection, 2016
Katrien Lagrou, Mihai Mareș, Maiken C Arendrup   +2 more
exaly   +2 more sources

Assessment of the In Vitro and In Vivo Antifungal Activity of NSC319726 against Candida auris

Microbiology Spectrum, 2021
Candida auris is an emerging yeast pathogen of candidemia with the ability to develop resistance to all current antifungal drug classes. Novel antifungal therapies against C. auris are warranted. NSC319726 is a thiosemicarbazone with an inhibitory effect
Jizhou Li, Alix T. Coste, Daniel Bachmann, Dominique Sanglard, Frederic Lamoth   +4 more
doaj   +1 more source